ME Therapeutics Holdings (OTCPK:METX.F) - Stock Price, News & Analysis

METX.F Stock Overview

A preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. More details

METX.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap ($83M)

ME Therapeutics Holdings Inc. Competitors

Entera Bio

NasdaqCM:ENTX

US$59.3m

Immuneering

NasdaqGM:IMRX

US$63.7m

Celularity

NasdaqCM:CELU

US$62.7m

X4 Pharmaceuticals

NasdaqCM:XFOR

US$60.1m

Price History & Performance

Summary of all time highs, changes and price drops for ME Therapeutics Holdings
Historical stock prices
Current Share Price	CA$2.95
52 Week High	CA$2.95
52 Week Low	CA$2.95
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	METX.F	US Biotechs	US Market
7D	0%	4.3%	1.6%
1Y	n/a	18.8%	32.3%

Return vs Industry: Insufficient data to determine how METX.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how METX.F performed against the US Market.

Price Volatility

Is METX.F's price volatile compared to industry and market?
METX.F volatility
METX.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: METX.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine METX.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	n/a	Salim Dhanji	www.metherapeutics.com

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate is a novel antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.

ME Therapeutics Holdings Inc. Fundamentals Summary

How do ME Therapeutics Holdings's earnings and revenue compare to its market cap?
METX.F fundamental statistics
Market cap	US$60.44m
Earnings (TTM)	US$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is METX.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
METX.F income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$0
Earnings	US$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did METX.F perform over the long term?

See historical performance and comparison

ME Therapeutics Holdings OTCPK:METX.F Stock Report